The Company
www.immuron.com.au
Immuron Limited is a commercial and clinical stage publicly listed Australian biopharmaceutical company with a proprietary technology platform focused on the development and commercialization of a novel class of specifically targeted polyclonal antibodies that we believe can address significant unmet medical needs. The company was incorporated under the laws of Australia in 1994 and has been listed on the Australian Securities Exchange (ASX), since April 30, 1999 and our ordinary shares trade under the symbol “IMC.”. Immuron completed an initial public offering on the NADAQ Capital Market in June 2017 and our American Depositary Shares and warrants are listed on NASDAQ under the symbols “IMRN” and “IMRNW”, respectively. Each ADS represents 40 of our ordinary shares, no par value.
youtu.be/SP-O2W0vXhM
Immuron has just released a study of its Travelan tablets by the US Department of Defense, which shows its effectiveness in preventing traveller’s diarrhoea — in each of 180 strains tested.
Dr Kanellos describes it appropriately as a “shock and awe” approach, targeting bacteria the likes of salmonella, food poisoning and Shigella – a disease estimated to cause 80 million to 165 million cases of disease worldwide according to the US Center for Disease Control and Prevention.
Pipeline
www.immuron.com.au/product-pipeline/
The Technicals
Looking at the weekly chart here the average volume on this stock since 2008 been roughly 300k shares. Looks like a breakout pattern with avg volume 4 mil.
www.immuron.com.au
Immuron Limited is a commercial and clinical stage publicly listed Australian biopharmaceutical company with a proprietary technology platform focused on the development and commercialization of a novel class of specifically targeted polyclonal antibodies that we believe can address significant unmet medical needs. The company was incorporated under the laws of Australia in 1994 and has been listed on the Australian Securities Exchange (ASX), since April 30, 1999 and our ordinary shares trade under the symbol “IMC.”. Immuron completed an initial public offering on the NADAQ Capital Market in June 2017 and our American Depositary Shares and warrants are listed on NASDAQ under the symbols “IMRN” and “IMRNW”, respectively. Each ADS represents 40 of our ordinary shares, no par value.
youtu.be/SP-O2W0vXhM
Immuron has just released a study of its Travelan tablets by the US Department of Defense, which shows its effectiveness in preventing traveller’s diarrhoea — in each of 180 strains tested.
Dr Kanellos describes it appropriately as a “shock and awe” approach, targeting bacteria the likes of salmonella, food poisoning and Shigella – a disease estimated to cause 80 million to 165 million cases of disease worldwide according to the US Center for Disease Control and Prevention.
Pipeline
www.immuron.com.au/product-pipeline/
The Technicals
Looking at the weekly chart here the average volume on this stock since 2008 been roughly 300k shares. Looks like a breakout pattern with avg volume 4 mil.
Comment:
journey.ct.events/vi...82-8ae7-f7279b4d9cde
Recent presentation only 15 mins, for upcoming catalysts
Recent presentation only 15 mins, for upcoming catalysts
Currently sitting at all time weekly poc